

"Express Mail" Label No. EV 337 295 947 US
Date of Deposit September 9, 2003

PATENT
Attorney Docket No.: 15270J-004765US
Client Reference No.: 209-US-CIP8BC5

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: _____



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DALE B. SCHENK et al.

Application No.: 09/724,288

Filed: November 28, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Sharon L. Turner

Art Unit: 1647

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

09/12/2003 KBTEHA1 00000012 201430 09724288
01 FC:1806 180.00 DA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/580,018, filed May 26, 2000 (Attorney Docket No. 15270J-004760US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

"Grant Application; Raso, Immunology of Alzheimer's Disease', 1/1998," cited by the Examiner in Application No. 09/579,690, is submitted herewith as cite no. 304. Application No. 09/579,690 is a commonly owned copending application directed to subject

matter related to the instant application. Applicant believes "1/1998" is not the publication date as alleged by the Examiner, but refers to the grant funding cycle. Applicants' further believe the date of public accessibility, if any, is unknown. Applicant wishes to bring to the Examiner's attention that a copy of a grant application believed to have been submitted by Victor Raso for NIH Grant 1 R43 AGI 5746-01 on August 29, 1997 was previously submitted in the initial IDS submitted September 10, 2001 as cite no. 144. Cite no. 144 is a redacted version of cite no. 304. Applicant obtained cite no. 144 under the Freedom of Information Act (FOIA). It is believed that the grant proposal would not have been accessible under FOIA before April 2, 1998, but the exact date of public accessibility, if any, is not known to Applicant.

The Assignee of the instant application is a licensee of U.S. Patent No. 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Application No. 09/441,140 is submitted herewith as cite number 283. U.S. Patent No. 5,688,651 was previously submitted in the IDS submitted September 10, 2001 as cite no. 16.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00;
09/723,927 filed 11/28/00;
09/724,762 filed 11/28/00;
09/724,102 filed 11/28/00;
09/724,489 filed 11/28/00;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;

09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00;
09/724,495 filed 11/27/00;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00;
09/724,961 filed 11/28/00;
09/580,018 filed 05/26/00;
09/724,552 filed 11/28/00;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00;
09/724,288 filed 11/28/00;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
09/585,817 filed 06/01/00;
09/724,567 filed 11/28/00;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00;
09/724,570 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;

09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01;
09/979,952 filed 04/04/02;
09/980,568 filed 03/12/02; and,
10/429,216 filed 05/02/03.

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/232,030 filed 08/30/02;
60/444,150 filed 02/01/03; and,
10/388,214 filed 03/12/03.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99; and,
60/136,655 filed 05/28/99.

Applicant also cites the following abandoned applications directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:


60/067,219 filed 12/02/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf



→

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 13

C m p l t e i f K n w n

| | |
|------------------------|-------------------|
| Application Number | 09/724,288 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Sharon L. Turner |
| Attorney Docket Number | 15270J-004765US |

U.S. PATENT DOCUMENTS

| Examiner | Cite No. ¹ | Document Number Number Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|-----------------------|---|--------------------------------|--|---|
| | 360 | 2003/0073655 A1 | 04-17-2003 | Chain | |
| | 370 | 2003/0068325 A1 | 04-10-2003 | Wang | |
| | 378 | 2002/0197258 A1 | 12-26-2003 | Ghanbari et al. | |
| | 366 | 2002/0187157 A1 | 12-12-2002 | Jensen et al. | |
| | 377 | 2002/0168377 A1 | 11-14-2002 | Schaetzel | |
| | 340 | 2002/0162129 A1 | 10-31-2002 | Lannfelt | |
| | 395 | 2002/0160394 A1 | 10-31-2002 | Wu | |
| | 326 | 2002/0136718 A1 | 09-26-2002 | Raso | |
| | 379 | 2002/0132268 A1 | 09-19-2002 | Chang et al. | |
| | 365 | 2002/0133001 A1 | 09-19-2002 | Gefer et al. | |
| | 325 | 2001/0102261 A1 | 08-01-2002 | Raso | |
| | 362 | 2002/0094335 A1 | 07-18-2002 | Chalifour et al. | |
| | 306 | 6,417,178 B1 | 07-09-2002 | Klunk et al. | |
| | 376 | 2002/0086847 A1 | 07-04-2002 | Chain | |
| | 405 | 6,399,314 B1 | 06-04-2002 | Krishnamurthy | |
| | 342 | 2002/0009445 A1 | 01-24-2002 | Du et al. | |
| | 267 | 6,294,171 B2 | 09-25-2001 | McMichael | |
| | 381 | 2001/0021769 A1 | 09-13-2001 | Prusiner | |
| | 401 | 6,284,533 B1 | 09-04-2001 | Thomas | |
| | 234 | 6,284,221 B1 | 09-04-2001 | Schenk, et al. | |
| | 300 | 2001/0018053 A1 | 08-30-2001 | McMichael | |
| | 230 | 6,262,335 B1 | 07-17-2001 | Hsiao et al. | |
| | 345 | 2002/0077288 A1 | 06-21-2001 | Frangione | |
| | 231 | 6,114,133 | 09-05-2000 | Seubert et al. | |
| | 221 | 5,989,566 | 11-23-1999 | Cobb et al. | |
| | 346 | 5,935,927 | 08-10-1999 | Vitek et al. | |
| | 382 | 5,846,533 | 12-08-1998 | Prusiner | |
| | 321 | 5,837,672 | 11-17-1998 | Schenk et al. | |
| | 353 | 5,824,322 | 10-20-1998 | Balasubramanian | |
| | 357 | 5,776,468 B1 | 07-07-1998 | Hauser et al. | |
| | 380 | 5,750,361 | 05-12-1998 | Prusiner et al. | |
| | 373 | 5,721,130 | 02-24-1998 | Seubert et al. | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60035092 v1



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|-------------------|
| Substitute for form 1449A/PTO | | | | C mplete if Kn wn | |
| | | | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/724,288 |
| | | | | Filing Date | November 28, 2000 |
| | | | | First Named Inventor | Dale B. Schenk |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | Sharon L. Turner |
| Sheet | 2 | of | 13 | Attorney Docket Number | 15270J-004765US |

| | | | | | |
|--|-----|--------------|------------|---------------|--|
| | 356 | 5,622,701 | 04-22-1997 | Berg | |
| | 320 | 5,593,846 | 01-14-1997 | Schenk et al. | |
| | 358 | 5,583,112 B2 | 12-10-1996 | Kensil et al. | |
| | 403 | 5,464,823 | 11-07-1995 | Lehrer et al. | |
| | 284 | 5,231,170 | 07-27-1993 | Averback | |
| | 402 | 4,713,366 | 12-15-1987 | Stevens | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|---------------------------|--|---|
| Examiner | Cite No. ¹ | Document Number Number Kind Code ² (if known) | Filing Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | 296 | 60/254,465 | 12-08-2000 | Holtzman et al. | |
| | 297 | 60/254,498 | 12-08-2000 | Holtzman et al. | |
| | 305 | 09/724,842 | 11-28-2000 | Chalifour et al. | |
| | 295 | 60/184,601 | 02-24-2000 | Holtzman et al. | |
| | 282 | 60/169,687 | 12-08-1999 | Chain | |
| | 242 | 60/168,594 | 11-29-1999 | Chalifour et al. | |
| | 283 | 09/441,140 | 11-16-1999 | Solomon et al. | |
| | 299 | 60/186,295 | 03-01-2000 | Rasmussen et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|---------------------------|---------------------|--------------------------------------|------------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD- YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | 343 | EP | 1 172 378 | A1 | 01-16-2002 | | | |
| | 351 | WO | 02/34878 | A2 | 05-02-2002 | | | |
| | 352 | WO | 02/34777 | A1 | 05-02-2002 | | | |
| | 341 | WO | 02/03911 | A2 | 04-07-2001 | | | |
| | 344 | WO | 01/90182 | A2 | 11-29-2001 | | | |
| | 348 | WO | 01/77167 | A2 | 10-18-2001 | | | |
| | 294 | WO | 01/62801 | A2 | 08-30-2001 | | | |
| | 301 | WO | 01/62284 | A2 | 03-01-2000 | | | |
| | 298 | WO | 01/42306 | A2 | 06-14-2001 | | | |
| | 243 | WO | 01/39796 | A2 | 06-07-2001 | | | |
| | 322 | WO | 00/72880 | A2, A3 | 12-07-2000 | | | |
| | 323 | WO | 00/72876 | A2, A3 | 12-07-2000 | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60035092 v1



→

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 13

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/724,288 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Sharon L. Turner |
| Attorney Docket Number | 15270J-004765US |

| | | | | | | | |
|--|-----|----|----------|----|------------|--|--|
| | 324 | WO | 00/72870 | A1 | 12-07-2000 | | |
| | 240 | WO | 00/43039 | A1 | 07-27-2000 | | |
| | 331 | WO | 99/06545 | A2 | 11-02-1999 | | |
| | 383 | WO | 97/10505 | A1 | 03-20-1997 | | |
| | 227 | WO | 95/11008 | A2 | 04-27-1995 | | |

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Patents, Washington, DC 20231
60035092 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 13

Complete if Known

| | |
|------------------------|-------------------|
| Applicati n Numb r | 09/724,288 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Sharon L. Turner |
| Attorney Docket Number | 15270J-004765US |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | 391 | AGUZZI et al., "Prion research: the next frontiers," <u>Nature</u> , 389:795-798 (1997). | |
| | 393 | AKIYAMA et al., "Inflammation and Alzheimer's disease," <u>Neurobiology of Aging</u> , 21:383-421 (2000). | |
| | 372 | AKIYAMA et al., "Occurrence of the Diffuse Amyloid β -Protein (A β) Deposits With Numerous A β -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <u>Glia</u> , 25:324-331 (1999). | |
| | 228 | BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," <u>J. Mol. Biol.</u> , 225(4): 1075-1093 (1992). | |
| | 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET. | |
| | 404 | BENJAMINI and LESKOWITZ, from <u>IMMUNOLOGY A Short Course</u> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York. | |
| | 327 | CAMERON, "Recent Advances in Transgenic Technology," <u>Molecular Biotechnology</u> , 7:253-265 (1997). | |
| | 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharm.</u> , 15:414A-414B (1992). | |
| | 224 | Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm , last updated May 16, 2002. | |
| | 266 | CHAPMAN, "Model behavior," <u>Nature</u> , 408:915-916 (2000). | |
| | 349 | CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003). | |
| | 222 | Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.) | |

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60035092 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/724,288 | | |
| | | Filing Dat | November 28, 2000 | | |
| | | First Named Inventor | Dale B. Schenk | | |
| | | Art Unit | 1647 | | |
| | | Examiner Name | Sharon L. Turner | | |
| Sheet | 5 | of | 13 | Attorney Docket Number | 15270J-004765US |

| | | | |
|--|-----|---|--|
| | 332 | CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," <u>Progress in Brain Research</u> , Van Leeuwen et al. Eds, 117:327-337 (1998). | |
| | 307 | CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-9 (2000). | |
| | 302 | CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999). | |
| | 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000). | |
| | 333 | CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000) | |
| | 286 | CORDELL, B., " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994). | |
| | 287 | COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993). | |
| | 293 | DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998). | |
| | 220 | Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. - comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.) | |
| | 390 | DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," <u>Biochem. J.</u> , 320:53-570 (1996). | |
| | 363 | DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?" <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003). | |
| | 318 | DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <u>Neurology</u> , 57(5):801-5 (2001). | |
| | 288 | DUMERY et al., " β -Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60035092 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|----|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Applicati n Numb r | 09/724,288 |
| | | | | Filing Dat | November 28, 2000 |
| | | | | First Named Inventor | Dale B. Schenk |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | Sharon L. Turner |
| Sheet | 6 | of | 13 | Attorney Docket Number | 15270J-004765US |

| | | | |
|--|-----|---|--|
| | 225 | Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/18/2002). | |
| | 226 | Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002) | |
| | 289 | ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?", <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001). | |
| | 328 | FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" <u>Alzheimer's and Parkinson's Diseases</u> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). | |
| | 386 | FRATUTSCHY et al., "Effects of injected Alzheimer β -amyloid cores in rat brain," <u>PNAS</u> , 88:8362-8366 (1991). | |
| | 246 | FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001). | |
| | 245 | FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of Neuroimmunology</u> , 95:136-142 (1999). | |
| | 247 | FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000). | |
| | 248 | FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998). | |
| | 244 | FRENKEL, et al., "Modulation of Alzheimer's β -amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 106:23-31 (2000). | |
| | 249 | FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). | |
| | 364 | FURLAN et al., "Vaccination with amyloid- β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <u>Brain</u> , 126:285-291 (2003). | |
| | 251 | GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60035092 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|-----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/724,288 | | |
| | | Filing Date | November 28, 2000 | | |
| | | First Named Inventor | Dale B. Schenk | | |
| | | Art Unit | 1647 | | |
| | | Examiner Name | Sharon L. Turner | | |
| Sheet | 7 | of | 13 | Attorney Docket Number | 15270J-004765US |

| | |
|-----|--|
| 252 | GEDDES, "N-terminus truncated β -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999). |
| 253 | GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998). |
| 388 | GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <u>Ann. Rev. Med.</u> , 46:57-65 (1995). |
| 397 | GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," <u>PNAS</u> , 96:3108-3113 (1999). |
| 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998). |
| 237 | GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949). |
| 254 | GRUBECK-LOEBENSTEIN, et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?", <u>TINS</u> , 23:114 (2000). |
| 241 | HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <u>Nature</u> , 359(6393):322-5 (1992). |
| 255 | HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995). |
| 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", <u>Immunology</u> , Vol. 78: 643-649 (1993). |
| 236 | HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 201:61-69 (1991). |
| 256 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987). |
| 374 | JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51, Raven Press, Ltd., New York (1995). |
| 308 | JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-82 (2000). |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60035092 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 13

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/724,288 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Sharon L. Turner |
| Attorney Docket Number | 15270J-004765US |

| | |
|-----|--|
| 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997). |
| 334 | JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767 (1991). |
| 371 | JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β -Amyloid Peptide (1-43) in Transfected 293 Cells," <u>Biochemical and Biophysical Research Communications</u> , 220:710-718 (1996). |
| 347 | JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <u>Infection and Immunity</u> , May:497-502 (1981). |
| 258 | KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995). |
| 389 | KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002). |
| 259 | LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997). |
| 260 | LEMERE, et al., "Nasal A β treatment induces anti-A β antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000). |
| 261 | MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994). |
| 263 | MANN, et al., "Amyloid β protein (A β) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A β ₄₂₍₄₃₎ ," <u>Annals of Neurology</u> , 40:149-156 (1996). |
| 262 | MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 196:105-108 (1995). |
| 335 | MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001). |
| 309 | MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <u>Physiol Rev.</u> 77(4):1081-132 (1997). |

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60035092 v1



→

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|--------------------------------|-------------------|------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | C m p l t e i f K n w n | | | |
| | | Application Number | 09/724,288 | | |
| | | Filing Date | November 28, 2000 | | |
| | | First Named Inventor | Dale B. Schenk | | |
| | | Art Unit | 1647 | | |
| | | Examiner Name | Sharon L. Turner | | |
| Sheet | 9 | of | 13 | Attorney Docket Number | 15270J-004765US |

| | | | |
|--|-----|---|--|
| | 264 | MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992). | |
| | 238 | MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-166 (1998). | |
| | 265 | MENA, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995). | |
| | 310 | MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000). | |
| | 367 | MONSONEGO et al., "Immune hyporesponsiveness to amyloid β -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001). | |
| | 311 | MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-5 (2000). | |
| | 233 | MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-65 (1989). | |
| | 359 | MUNCH et al., "Potential neurotoxic inflammatory response to A β vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087. | |
| | 355 | MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York. | |
| | 354 | MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany. | |
| | 250 | NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995). | |
| | 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (A β) subtypes (A β 40 and A β 42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <u>Neuroscience Letters</u> , 201:151-154 (1995). | |
| | 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998). | |


| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60035092 v1

+



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 09/724,288 |
| | | Filing Date | November 28, 2000 |
| | | First Named Inventor | Dale B. Schenk |
| | | Art Unit | 1647 |
| | | Examiner Name | Sharon L. Turner |
| Sheet 10 of 13 | Attorney Docket Number | 15270J-004765US | |

| | | |
|-----|---|--|
| 235 | NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys. Acta</u> , 104:480-486 (1965). | |
| 350 | NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003). | |
| 329 | NIEMANN, "Transgenic farm animals get off the ground," <u>Transgenic Research</u> 7:73-75 (1998). | |
| 398 | PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 7:703-707 (2001). | |
| 406 | PAN et al., "Antibodies to β -Amyloid Decrease the Blood-to-Brain Transfer of β -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):609-615 (2002). | |
| 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987). | |
| 336 | PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002). | |
| 232 | PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996). | |
| 269 | PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996). | |
| 394 | PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993). | |
| 304 | RASO, V.A., Grant application # 1 R43 AG1 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown). | |
| 279 | SAITO et al., "Vector-mediated delivery of ^{125}I -labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A β^{1-40} vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995).** | |
| 278 | SAITOH, N. et al., "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991). | |
| 277 | SASAKI et al., "Human choroid plexus is a uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60035092 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|----|----|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | C mplete if Known | |
| | | | | Application Number | 09/724,288 |
| | | | | Filing Date | November 28, 2000 |
| | | | | First Named Inventor | Dale B. Schenk |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | Sharon L. Turner |
| Sheet | 11 | of | 13 | Attorney Docket Number | 15270J-004765US |

| | | | |
|--|-----|---|--|
| | 312 | SCHENK, et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001). | |
| | 270 | SCHENK, et al., " β -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000). | |
| | 313 | SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998). | |
| | 330 | SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000). | |
| | 396 | SIGURDSSON et al., "Anti-priori antibodies for prophylaxis following prion exposure in mice," <u>Neurosciences Letters</u> , 336:185-187 (2003). | |
| | 384 | SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002). | |
| | 314 | SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000). | |
| | 400 | SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," <u>Neurobiology of Aging</u> , 23:1001-1008 (2002). | |
| | 315 | SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci.</u> , 920:206-8 (2000). | |
| | 368 | SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992). | |
| | 337 | SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech.</u> , 18(1):34-39 (2000). | |
| | 319 | SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <u>Nat Rev Neurosci.</u> 2(8):595-8 (2001). | |
| | 316 | SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. <u>Nat Med.</u> 4(7):822-6 (1998). | |
| | 369 | SPOONER et al., "The generation and characterization of potentially therapeutic A β antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002). | |
| | 271 | ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1999). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60035092 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 12 of 13 | | Complete if Known | |
| | | Applicant Number | 09/724,288 |
| | | Filing Date | November 28, 2000 |
| | | First Named Inventor | Dale B. Schenk |
| | | Art Unit | 1647 |
| | | Examiner Name | Sharon L. Turner |
| | | Attorney Docket Number | 15270J-004765US |

| | |
|-----|--|
| 338 | STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <u>The Journal of Neuroscience</u> , 22(17):7380-7388 (September 1, 2002). |
| 361 | SU et al., "Intravascular infusions of soluble β -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999). |
| 272 | SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996). |
| 392 | TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003). |
| 399 | TAN et al., "Amyloidosis," <u>Histopathology</u> , 25:403-414 (1994). |
| 339 | TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4299-4303 (1995). |
| 273 | THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000). |
| 276 | TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996). |
| 375 | TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopathy using end-specific antibodies for A β 40 and A β 42: immunohistochemical evidence for amyloid β protein," <u>Neuroscience Letters</u> , 2002:77-80 (1995). |
| 317 | VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <u>DNA Cell Biol.</u> (11):713 21 (2001). |
| 274 | WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000). |
| 387 | WELDON et al., "Neurotoxicity of A β Peptide: Confocal Imaging of Cellular Changes Induced by - Amyloid in Rat CNS <i>In Vivo</i> ," <u>Society for Neuroscience Abstracts</u> , 22(Part 1) (1996). **** |
| 223 | WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.) |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60035092 v1



→

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

| | | | | | |
|---|----|----|----|--------------------------|-------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/724,288 |
| | | | | Filing Date | November 28, 2000 |
| | | | | First Named Inventor | Dale B. Schenk |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | Sharon L. Turner |
| Sheet | 13 | of | 13 | Attorney Docket Number | 15270J-004765US |

| | | | |
|--|-----|---|--|
| | 385 | WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):-574-587 (2002). | |
| | 275 | WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). | |
| | 292 | YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998). | |
| | 290 | YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60035092 v1

+